Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells

14 Sept 2021

Abstract excerpt

Doxorubicin (Dox) is one of the most commonly used anthracyclines for the treatment of solid and hematological tumors such as B-/T cell acute lymphoblastic leukemia (ALL). Dox compromises topoisomerase II enzyme functionality, thus inducing structural damages during DNA replication and causes direct damages intercalating into DNA double helix. Eukaryotic cells respond to DNA damages by activating the ATM-CHK2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34519926
DOI: 10.1007/s10565-021-09640-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cellsPMID 34519926Read ↗

Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA DamageSemantic proximity Read ↗

Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA DamageSemantic proximity Read ↗

New insights into the activities and toxicities of the old anticancer drug doxorubicinSemantic proximity Read ↗

The cell cycle checkpoint inhibitors in the treatment of leukemiasSemantic proximity Read ↗

Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapySemantic proximity Read ↗

Differential DNA Damage Response of Peripheral Blood Lymphocyte Populations.Semantic proximity Read ↗

Unleashing Chk1 in cancer therapySemantic proximity Read ↗

Polo-like Kinase-1, Aurora Kinase A and Wee1 Kinase Are Novel Therapeutic Targets in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in CancerSemantic proximity Read ↗

Cell cycle checkpoint proteins and cellular response to treatment by anticancer agents.Semantic proximity Read ↗

The Radiosensitizing Potential of CC-115, PIK-75 and M3814 DNA-PK Inhibitors for Breast Cancer Targeted RadiotherapySemantic proximity Read ↗

Promising Anti-leukemic Effect of Zataria Multiflora Extract in Combination with Doxorubicin to Combat Acute Lymphoblastic Leukemia Cells (Nalm-6)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.